Loading...
Market
Public health response to puberty blockers cancer risk by end of 2024?
2
Resolution / Starting Odds
Issue warning • 25%
Update guidelines • 25%
No changes • 25%
Other • 25%
Reports from public health agencies or major health news outlets
Story
Study Links Puberty Blockers to 26.5x Higher Testicular Cancer Risk
Nov 24, 2024, 01:49 AM
New evidence suggests that long-term treatment with puberty blockers and cross-sex hormones may significantly increase the risk of testicular cancer. A study involving 458 men found that they are 26.5 times more likely to develop testicular cancer after undergoing such treatments. Testicular cancer rates are 26.5x HIGHER in males seeking orchiectomies. This raises serious concerns about the safety and ethical implications of using these treatments in young individuals.
View original story
Similar markets
Proven safe and effective • 25%
Proven ineffective • 25%
Proven unsafe • 25%
Inconclusive results • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive outcome • 25%
Trials not completed • 25%
Support the ruling • 25%
Oppose the ruling • 25%
Neutral stance • 25%
Other • 25%
Safe and effective • 25%
Unsafe • 25%
Inconclusive • 25%
Trial not completed • 25%
Yes • 50%
No • 50%
Allowed with parental consent • 25%
Allowed without parental consent • 25%
Not allowed • 25%
Other • 25%
Support the ban • 25%
Oppose the ban • 25%
Call for more research • 25%
Remain neutral • 25%
Positive outcome • 25%
Negative outcome • 25%
Inconclusive • 25%
Trial not completed • 25%